CVS Health Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting total revenues of $108,399 million and net income attributable to CVS Health of $2,172 million for the third quarter.

Key Highlights

  • Total revenues of $108,399 million for the three months ended September 30, 2026, up from $102,871 million in the same period of 2025, according to the filing.
  • Net income attributable to CVS Health of $2,172 million for Q3 2026, compared to a net loss of $3,975 million in Q3 2025, which included a goodwill impairment charge of $5,725 million.
  • Diluted earnings per share of $1.68 for the third quarter of 2026, versus a diluted loss per share of $3.13 in the third quarter of 2025.
  • Nine-month total revenues of $314,921 million for the period ended September 30, 2026, compared to $296,374 million for the same period in 2025.
  • Net cash provided by operating activities of $15,318 million for the nine months ended September 30, 2026, compared to $7,249 million for the nine months ended September 30, 2025.
  • Total assets of $258,075 million as of September 30, 2026, versus $253,538 million as of December 31, 2025.
  • 1,279,474,188 shares of common stock issued and outstanding as of October 28, 2026, as reported on the filing's cover page.

CVS Health Third-Quarter 2026 Financial Results and Balance Sheet Position

According to the quarterly report filed with the SEC, NYSE:CVS reported total revenues of $108,399 million for the three months ended September 30, 2026, broken down as $69,225 million from products, $34,566 million from premiums, $3,961 million from services, and $647 million from net investment income. Total operating costs for the quarter were $104,833 million, resulting in operating income of $3,566 million. After interest expense of $747 million and an income tax provision of $678 million, the company reported net income attributable to CVS Health of $2,172 million.

For the nine months ended September 30, 2026, the filing disclosed total revenues of $314,921 million and net income attributable to CVS Health of $8,094 million, or $6.29 per diluted share. This compares to a net loss attributable to CVS Health of $1,175 million, or $0.93 per diluted share, for the nine months ended September 30, 2025, a period that included a goodwill impairment charge of $5,725 million. Health care costs for the nine-month period were reported at $93,159 million in 2026 versus $92,472 million in 2025.

The condensed consolidated balance sheet as of September 30, 2026, showed total assets of $258,075 million and total liabilities of $177,386 million, leaving total shareholders' equity of $80,689 million. Long-term debt stood at $57,223 million, down from $60,502 million at December 31, 2025. Cash and cash equivalents increased to $11,738 million from $8,453 million at year-end 2025. Net cash provided by operating activities for the nine months ended September 30, 2026, was $15,318 million, compared to $7,249 million for the same period in 2025.

What Was Disclosed

CVS Health filed its quarterly report covering the three and nine months ended September 30, 2026, disclosing revenues, earnings, balance sheet data, and cash flows. The prior-year quarter included a $5,725 million goodwill impairment charge that is absent from the current-year results.